Hypha Discovery is a UK-based biotechnology company that supports pharmaceutical and agrochemical companies by producing metabolites and new derivatives of drugs and pesticides in discovery and development. Hypha is an expert in the scalable synthesis of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the production, purification and structure elucidation of natural products.
NEW PolyCYPs® biocatalysis kits
Hypha’s PolyCYPs® kits provide a fast and scalable way to access CYP-derived drug metabolites and derivatives formed by oxidation at aliphatic or aromatic moieties. Download a pdf of the PolyCYPs brochure.
Click here to find out more about PolyCYPs kits
NEWS & EVENTS
11th – 15th November 2019, University of Copenhagen, Denmark Our Head of Synthetic Chemistry, Lisbet Kvaerno is organising this conference at the University of Copenhagen on organic chemistry in the pharmaceutical, agrochemical and contract manufacturing industries
18th – 19th February 2020, Manchester, UK Hypha will be giving a talk on LSF using PolyCYPs enzymes Hypha’s PolyCYPs enzymes have been routinely used by pharma and agchem companies for producing metabolites. One application involves direct comparison of radiometric profiles of PolyCYPs and regulatory study samples. In this study by Charles River, a radiolabelled agrochemical compound was incubated with PolyCYPs and the metabolites matched with those detected in goat faeces, as part of an mass balance and disposition study, thereby providing an immediate route to access and scale-up metabolites. Click here for a link to an illustration of the results of this study.Come and meet us at the following events
Organic Chemistry in the Pharmaceutical, Agrochemical and Contract Manufacturing Industries
SCI/RSC Applied Late-stage Functionalisation: Where Chemistry meets Biology
Hypha’s latest metabolite project update
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics: Let us know if you would like a copy of a paper published last year in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d In a recent newsletter we described a case study illustrating the use of microbial biotransformation to produce scalable quantities of glucuronides, focusing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs. Access a pdf of the newsletter on glucuronides of carboxylic acid-containing drugsDownload a copy of our brochure on drug metabolites and C-H activated derivatives
